Substance / Medication

Patisiran

Overview

Active Ingredient
patisiran
RxNorm CUI
2053490

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review.
Karimi Mohammad Amin, Esmaeilpour Moallem Fatemeh, Gholami Chahkand Mohammad Sadra et al. · Front Neurol · 2024
PMID: 39286810Meta-AnalysisFull text (PMC)
Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis.
Mesquita Claudio Tinoco, Schwartzmann Pedro, Correia Edileide Barros et al. · Arq Bras Cardiol · 2025
PMID: 40243852RCTFull text (PMC)
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer Mathew S, Kale Parag, Fontana Marianna et al. · N Engl J Med · 2023
PMID: 37888916RCTFull text (PMC)
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
Lin Kon-Ping, Yang Chih-Chao, Lee Yi-Chung et al. · J Formos Med Assoc · 2024
PMID: 38548524Trial
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
Schmidt Hartmut H, Wixner Jonas, Planté-Bordeneuve Violaine et al. · Am J Transplant · 2022
PMID: 35213769TrialFull text (PMC)
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams David, Polydefkis Michael, González-Duarte Alejandra et al. · Lancet Neurol · 2021
PMID: 33212063Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Patisiran (substance)
SNOMED CT
773605008
UMLS CUI
C3896714
RxNorm CUI
2053490

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.